Oncolytics Biotech gains third orphan status for Reolysin
Canada’s Oncolytics Biotech (TSX:ONC0) revealed today that the US Food and Drug Administration has granted Orphan Drug designation for its lead product candidate, Reolysin (pelareorep), a proprietary formulation of human reovirus, for the treatment of primary peritoneal cancers.
Shares of Oncolytics leapt 13.1% to $1.21 in pre-market trading, having already rocketed nearly 47% the previous day.
"This is the fourth indication for which we have received Orphan Drug designation in the United States, and the third in a gynecological cancer indication," said Brad Thompson, president and chief executive of Oncolytics, adding: "These Orphan Drug designations are an important step for Oncolytics' ongoing program to develop and commercialize Reolysin as a therapeutic for targeted cancer patient populations."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze